Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsTranslating TrialsCase-Based Peer PerspectivesPodcastsVideosShorts
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

G. Thomas Budd, MD

Advertisement

Articles by G. Thomas Budd, MD

G. Thomas Budd on Genomic Profiling for Targeted Therapies

ByG. Thomas Budd, MD
January 13th 2016

G. Thomas Budd, MD, medical oncologist, Taussig Cancer Center at Cleveland Clinic, discusses genomic profiling for targeted therapies.

Advertisement

Latest Updated Articles

  • G. Thomas Budd on Genomic Profiling for Targeted Therapies
    G. Thomas Budd on Genomic Profiling for Targeted Therapies

    January 13th 2016



Advertisement
Advertisement

Trending on Oncology Nursing News

1

NCCN Survey: US Cancer Centers Face Generic Oncology Drug Shortages

2

Solavia Decision Suite: Key Clinical Insights for APPs and PAs

3

FDA Grants Final Approval to Cabozantinib Capsules Across Multiple Solid Tumor Indications

4

FDA Approves Frontline Sevabertinib for HER2-Mutant Advanced NSCLC Patients

5

Frontline Sevabertinib Approved in HER2-Mutant NSCLC: Nursing Priorities

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us